Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 10/20 | 0.51 |
| ▸ | UBA3 | Q8TBC4 | 9/20 | 0.51 |
| ▸ | UBA6 | A0AVT1 | 2/20 | 0.51 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.51 |
| ▸ | ATG7 | O95352 | 1/20 | 0.51 |
| ▸ | UBA7 | P41226 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | GRK5 | P34947 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | NEDD8 | Q15843 | 1/20 | 0.38 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12652425 | 0.90 | NAE1 (0.44) | NAE1UBA3UBA6SAE1ATG7 | |
| SCHEMBL17898105 | 0.84 | NAE1 (0.71) | NAE1UBA3UBA6SAE1ATG7 | |
| SCHEMBL12566826 | 0.83 | NAE1 (0.71) | NAE1UBA3UBA6SAE1ATG7 | |
| SCHEMBL12566819 | 0.77 | NPC1 (0.58) | — | |
| SCHEMBL1798415 | 0.77 | UBA6 (0.58) | NAE1UBA3UBA6SAE1ATG7 | |
| SCHEMBL1798413 | 0.77 | UBA6 (0.58) | NAE1UBA3UBA6SAE1ATG7 | |
| SCHEMBL1798707 | 0.77 | NAE1 (0.49) | NAE1UBA3UBA6SAE1ATG7 | |
| SCHEMBL12652414 | 0.76 | UBA6 (0.47) | NAE1UBA3UBA6SAE1ATG7 | |
| SCHEMBL17889829 | 0.76 | BCHE (0.45) | NAE1UBA3UBA6SAE1ATG7 | |
| SCHEMBL1803817 | 0.76 | BCHE (0.45) | NAE1UBA3UBA6SAE1ATG7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENIUM PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | NAE1 257/4885UBA3 235/4885UBA6 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.